Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 13, 2025
SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended June 30, 2025.
Read more at globenewswire.com
